Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Bronchiolitis obliterans syndrome (BOS) is the major limitation to survival after lung transplantation. Acute rejection, its main risk factor, is characterized by perivascular/bronchiolar leukocyte infiltration. BOS is characterized by persistent peribronchiolar leukocyte recruitment leading to airway fibrosis and obliteration. The specific mechanism(s) by which these leukocytes are recruited are unknown. Because MCP-1, acting through its receptor CCR2, is a potent mononuclear cell chemoattractant, we hypothesized that expression of this chemokine during an allogeneic-response promotes persistent recruitment of leukocytes and, ultimately, rejection. We found that elevated levels of biologically active MCP-1 in human bronchial lavage fluid (BALF) were associated with the continuum from acute to chronic allograft rejection. Translational studies in a murine model of BOS demonstrated increased MCP-1 expression paralleling mononuclear cell recruitment and CCR2 expression. Loss of MCP-1/CCR2 signaling, as seen in CCR2(-/-) mice or in WT mice treated with neutralizing antibodies to MCP-1, significantly reduced recruitment of mononuclear phagocytes following tracheal transplantation and led to attenuation of BOS. Lymphocyte infiltration was not reduced under these conditions. We suggest that MCP-1/CCR2 signaling plays an important role in recruitment of mononuclear phagocytes, a pivotal event in the pathogenesis of BOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,665
Boring, L., Gosling, J., Cleary, M., & Charo, I. F. (1998) · Nature · doi:10.1038/29788 · Cited by 1,965 · cited 1×
“Similarly, in a murine model of atherosclerosis, CCR2–/– crossed with ApoE–/– mice displayed a marked reduction in vessel obliteration secondary to a reduction in recruited mononuclear phagocytes within the lesions (35, 36).”
BackgroundSelf-citationMonocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant.
Carr, M. W., Roth, S. J., Luther, E., Rose, S. S., & Springer, T. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3652 · Cited by 1,198 · cited 1×
“MCP-1 is a CC chemokine, and it is a potent chemoattractant for mononuclear cells, specifically mononuclear phagocytes, CD45RO+ T lymphocytes, B cells, and NK cells (3, 4).”
BackgroundBoring, L., Gosling, J., Chensue, S. W., Kunkel, S. L., Farese, R. V., Broxmeyer, H. E., & Charo, I. F. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119798 · Cited by 1,096
Self-citationYousem, S. A., Berry, G. J., Cagle, P. T., Chamberlain, D. W., Husain, A. N., Hruban, R. H., Marchevsky, A. M., Ohori, N. P., Ritter, J. M., Stewart, S., et al. (1996) · PubMed · Cited by 842
Kuziel, W. A., Morgan, S. J., Dawson, T. C., Griffin, S., Smithies, O., Ley, K., & Maeda, N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.12053 · Cited by 709
Charo, I. F., Myers, S. J., Herman, A., Franci, C., Connolly, A. J., & Coughlin, S. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2752 · Cited by 705
Self-citationCc Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune Encephalomyelitis
Fife, B. T., Huffnagle, G. B., Kuziel, W. A., & Karpus, W. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.6.899 · Cited by 511 · cited 1×
“Similarly, other studies of chronic inflammatory diseases such as murine experimental autoimmune encephalomyelitis and rat induced glomerular fibrosis have demonstrated similar findings (26, 27).”
ResultTrulock, E. P. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.3.9117010 · Cited by 458
Arcasoy, S. M., & Kotloff, R. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904083401406 · Cited by 443
Cited by
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
“Similar results were obtained when CCL2 was neutralized, suggesting that a variety of CC-chemokines are involved [41,42].”
ResultFibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Integrating mechanisms of pulmonary fibrosis
Wynn, T. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110551 · Cited by 1,274
Langerhans cells renew in the skin throughout life under steady-state conditions
Merad, M., Manz, M. G., Karsunky, H., Wagers, A., Peters, W., Charo, I., Weissman, I. L., Cyster, J. G., & Engleman, E. G. (2002) · Nature Immunology · doi:10.1038/ni852 · Cited by 977
Self-citationLin, K. L., Suzuki, Y., Nakano, H., Ramsburg, E., & Gunn, M. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2562 · Cited by 442
Chen, J., Lau, Y. F., Lamirande, E. W., Paddock, C. D., Bartlett, J. H., Zaki, S. R., & Subbarao, K. (2010) · Journal of Virology · doi:10.1128/jvi.01281-09 · Cited by 399
Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury
Belperio, J. A., Keane, M. P., Burdick, M. D., Londhe, V., Xue, Y. Y., Li, K., Phillips, R. J., & Strieter, R. M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215849 · Cited by 366
Self-citationBlockade of CCR2 Ameliorates Progressive Fibrosis in Kidney
Kitagawa, K., Wada, T., Furuichi, K., Hashimoto, H., Ishiwata, Y., Asano, M., Takeya, M., Kuziel, W. A., Matsushima, K., Mukaida, N., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63292-0 · Cited by 330
Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?
Byrne, A. J., Maher, T. M., & Lloyd, C. M. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.004 · Cited by 315
Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications
Niu, J., & Kolattukudy, P. E. (2009) · Clinical Science · doi:10.1042/cs20080581 · Cited by 291
The use of recombinant factor VIIa in the treatment of bleeding disorders
Roberts, H. R., Monroe, D. M., & White, G. C. (2004) · Blood · doi:10.1182/blood-2004-06-2223 · Cited by 275
Lu, H., Huang, D., Ransohoff, R. M., & Zhou, L. (2011) · The FASEB Journal · doi:10.1096/fj.10-178939 · Cited by 254
The Inflammation–Fibrosis Link? A Jekyll and Hyde Role for Blood Cells during Wound Repair
Stramer, B. M., Mori, R., & Martin, P. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700811 · Cited by 251
D'Haese, J. G., Demir, I. E., Friess, H., & Ceyhan, G. O. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903540265 · Cited by 116
Metadata
- Authors
- Belperio, J. A., Keane, M. P., Burdick, M. D., Lynch, J. P., Xue, Y. Y., Berlin, A., Ross, D. J., Kunkel, S. L., Charo, I. F., & Strieter, R. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2001-08-15
- Volume
- 108
- Issue
- 4
- Pages
- 547-556
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2147571780
- Cited by
- 255
- References
- 29
- FWCI
- 16.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.